Invokamet xr® (metformin 1000 mg canagliflozin 50 mg) tablet patent?

I can help, but I need one quick clarification: are you asking for the patent status of Invokamet XR® (metformin ER + canagliflozin) in the U.S. specifically, or in another country (e.g., EU/UK/Canada)?

In the meantime, here’s the key point:

• Invokamet XR® is a combination product (canagliflozin + metformin ER), and patent protection is usually not just one patent—it’s typically multiple patents covering different aspects (the drug substance, the fixed-dose combination, formulations/extended-release technology, and use/indications).
• Generic approval and “patent expiration” can differ depending on whether the question is about:
  • canagliflozin patents (the brand can be affected by those),
  • metformin ER formulation patents,
  • the specific XR fixed-dose combination product,
  • and any regulatory exclusivities (e.g., Hatch-Waxman pediatric exclusivity, orphan exclusivity if applicable, etc.).

If you tell me the country (and whether you mean “active patents” vs “last expiration date” vs “FDA ANDA/listing”), I can look it up more precisely.

Please reply with:

1. Country (US/EU/UK/Canada/other)
2. Do you mean patent(s) related to the brand product “Invokamet XR” specifically, or the underlying canagliflozin patents?

Then I’ll give you the specific patent numbers and the relevant expiration/remaining status.